PRPO News and Press, Precipio Inc. From 06/08/23

NEW HAVEN, Conn., June 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 4,125,000 shares of the Com...

NEW HAVEN, Conn., June 07, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that several operational improvement initiatives which commenced at the start of the year have begun to impact the cash burn and bottom line profitabi...

NEW HAVEN, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a patient with a history of Chronic Myeloid Leukemia (CML) and p210 isoform expression which ...

2023-05-18 12:34:04 ET Precipio, Inc. (PRPO) Q1 2023 Earnings Conference Call May 17, 2023, 05:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Presentation Operator Welcome to the Precipio Q1 2023 Shareholder Upda...

2023-05-17 17:47:09 ET Precipio press release ( NASDAQ: PRPO ): Q1 GAAP EPS of -$0.13 misses by $0.02 . Revenue of $2.82M (+15.1% Y/Y) beats by $0.02M . For further details see: Precipio GAAP EPS of -$0.13 misses by $0.02, revenue of $2.82M beats by $0.02M

NEW HAVEN, Conn., May 17, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be discussing on today’s shareholders call several growth catalysts that management has been tracking. The Company believes that these catalysts coul...

NEW HAVEN, Conn., May 15, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q1-2023 corporate update call on May 17 th at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. ...

NEW HAVEN, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement with a new pathology services customer to utilize Precipio’s diagnostic services. Based on the customer’s size and ...

NEW HAVEN, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement with a new customer to bring HemeScreen™ technology into their laboratory. With each additional customer, Precipio continues to ...

2023-04-28 03:11:10 ET Specialty cancer diagnostics company Precipio ( NASDAQ: PRPO ) has been granted a 180-day extension by Nasdaq to allow the company to meet the required minimum $1.00 per share closing bid price for 10 consecutive business days. The stoc...